Replimune Group, Inc. (7R8)
FSX
Closed
Oct 9, 2026
Day's Range
11.3652 wk Range
1.43Overview - 7R8 - Replimune Group, Inc.
Key Statistics
Valuation
Enterprise Value
804.31M
P/E (Trailing)
‪-3.30‬
P/E (Forward)
‪-4.26‬
PEG Ratio
‪0.13‬
Price / Book
‪9.68‬
EV / EBITDA
‪-3.15‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-51.29%‬
Return on Equity
‪-134.28%‬
Ownership
Shares Outstanding
83.97M
Float
67.65M
Held by Insiders
‪1.64%‬
Held by Institutions
‪104.24%‬
Price stats
Beta
‪0.94‬
50-Day Avg
‪10.67‬
200-Day Avg
‪7.34‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 7R8 - Replimune Group, Inc.
Peers - 7R8 - Replimune Group, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- 7R8FSXReplimune Group, Inc.1.05BMarket Cap+68.50%52-week change-3.31P/E (Trailing)‪0.00%‬Profit Margin
- ANLFSXAnalog Devices Inc.179.11BMarket Cap+43.92%52-week change47.10P/E (Trailing)‪29.78%‬Profit Margin
- 0QFFSXModerna Inc.69.12BMarket Cap+87.76%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 64BFSXAstera Labs, Inc.53.43BMarket Cap+42.53%52-week change179.66P/E (Trailing)‪30.74%‬Profit Margin
- 1AEFSXargenx SE52.63BMarket Cap+28.29%52-week change36.62P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt50.36BMarket Cap+25.47%52-week change34.88P/E (Trailing)‪32.26%‬Profit Margin
- 42ZFSXRevolution Medicines, Inc.37.58BMarket Cap+78.78%52-week change-29.47P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - 7R8 - Replimune Group, Inc.
About
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
